CDK4 and ovarian carcinoma: Since CDK6 is a potential resistance marker of MEKi, as well as a single therapeutic target for ovarian cancer patients (Dall’Acqua et al. 2021), we selected palbociclib as the specific inhibitor of CDK4/6 to use in combination with MEKi.